News

Skyhawk, Celgene Partner to Develop Small Molecule Treatments for Huntington’s, Other Neurological Diseases

Skyhawk Therapeutics and Celgene have entered into a five-year global partnership to use Skyhawk’s STAR* technology platform to discover, advance, and commercialize new small-molecule therapies to treat patients with neurological diseases, including Huntington’s disease. The STAR* approach, which stands for “small-molecule therapies for alternative splicing in RNA,” aims to correct the…

Experts Seeking Tools to Assess Effectiveness of Targeted Huntington’s Therapies

Improved measures to accurately determine the effectiveness of treatments targeting Huntington’s disease are necessary, according to clinical neurologists and Huntington’s specialists. The editorial, “Improved metrics for Huntington’s disease trials,” reflects on recent advances made for the development of targeted agents that can effectively change the course of Huntington’s disease.

Novel Spotlights Daily Struggles of Patients and Families

“You Me Everything,” a novel about a single mom whose mother is diagnosed with Huntington’s disease, is helping to raise awareness of the condition. The story is also drawing attention to the struggles of patients and their loved ones. In writing the novel, British author Catherine Isaac sought…

Program Provides Second Opinion About Rare Disease Diagnosis, Care

A Rare Conditions Care Value (RCCV) program providing second opinions from experts for patients with rare diseases like Huntington’s disease was launched recently by two U.S. health management companies, Express Scripts and Pinnacle Care. The program, aptly named “Second Opinion,” offers another assessment regarding diagnosis and disease treatment from a specialist in the field,…